Published in Semin Oncol on September 11, 2015
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. Dis Markers (2016) 0.78
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. Oncology (Williston Park) (2015) 0.77
Potential role of immunotherapy in advanced non-small-cell lung cancer. Onco Targets Ther (2016) 0.77
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75
Targeted Therapies for the Treatment of Non-Small-Cell Lung Cancer: Monoclonal Antibodies and Biological Inhibitors. Hum Vaccin Immunother (2016) 0.75
FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival. Oncoimmunology (2016) 0.75
A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75
Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch (2017) 0.75
Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration. Clin Cancer Res (2017) 0.75
PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment. Oncotarget (2017) 0.75
Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Rev Anticancer Ther (2016) 0.75
[Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with Nivolumab]. Pathologe (2017) 0.75
[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. Pathologe (2016) 0.75